文献速递妇科

疾病进展对晚期卵巢癌患者健康相关生活质量的影响——PRIMA试验的汇总分析

Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
PubMed 文献 · Gynecol Oncol · 2022-07-15

PRIMA III期试验的事后分析纳入733例晚期卵巢癌患者,比较疾病进展前末次访视至治疗结束及后续24周内的健康相关生活质量。FOSI、EQ-5D-5L和EQ-VAS评分从进展前末次访视至治疗结束均恶化,并持续处于低水平。疾病进展对卵巢癌患者健康相关生活质量有负面影响,延长无进展生存期可能有助于维持生活质量。

要点

  • 疾病进展前末次访视至治疗结束,FOSI评分最小二乘均值变化为-2.1(95%CI -2.4, -1.7)。
  • EQ-5D-5L指数从进展前末次访视至治疗结束最小二乘均值变化为-4.6(95%CI -5.6, -3.5)。
  • EQ-VAS从进展前末次访视至治疗结束最小二乘均值变化为-7.9(95%CI -9.6, -6.3)。

核心结论

  • 疾病进展对卵巢癌患者的健康相关生活质量有负面影响。
  • 无进展生存期具有临床相关性,延长无进展生存期可能维持健康相关生活质量。

研究设计与样本

  • PRIMA III期试验的事后分析,患者为对一线铂类化疗有反应的晚期卵巢癌患者,随机接受每日一次口服尼拉帕利或安慰剂维持治疗。
  • 本事后分析纳入733例患者,比较疾病进展前末次访视与治疗结束及治疗后4、8、12、24周的健康相关生活质量。
  • 评估工具包括FOSI、EQ-5D-5L、EQ-VAS、EORTC-QLQ-C30和EORTC-QLQ-OV28。

主要发现

  • FOSI、EQ-5D-5L和EQ-VAS平均评分从进展前末次访视至治疗结束均恶化,并持续低至24周随访。
  • 从进展前末次访视至治疗结束,FOSI最小二乘均值变化为-2.1(95%CI -2.4, -1.7)。
  • 从进展前末次访视至治疗结束,EQ-5D-5L指数最小二乘均值变化为-4.6(95%CI -5.6, -3.5)。
  • 从进展前末次访视至治疗结束,EQ-VAS最小二乘均值变化为-7.9(95%CI -9.6, -6.3)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Progression-free survival (PFS) is an important early efficacy endpoint in ovarian cancer (OC) and its relevance to patients should be assessed. PRIMA, a phase III trial, assessed niraparib in patients with OC; this post hoc analysis examined the relationship between disease progression in OC and health-related quality of life (HRQoL). METHODS: The PRIMA trial randomized patients with advanced OC responsive to first-line platinum-based chemotherapy to once daily maintenance oral niraparib or placebo. This post hoc analysis evaluated the impact of disease progression on HRQoL by comparing HRQoL at the last visit pre-progression to end of treatment (EoT), and after 4, 8, 12, and 24 weeks. Assessments included the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI), the European Quality of Life Five Dimension Five Level questionnaire (EQ-5D-5L) and EQ Visual Analogue Scale (EQ-VAS), the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC-QLQ-C30), and the EORTC Quality of Life Questionnaire Ovarian Cancer module (EORTC-QLQ-OV28). RESULTS: This post hoc analysis included 733 patients. Mean FOSI, EQ-5D-5L, and EQ-VAS scores deteriorated from last visit pre-progression to EoT and remained low up to 24-week follow-up. Least squares mean changes from last visit pre-progression to EoT were -2.1 (95% confidence interval -2.4, -1.7) for FOSI, -4.6 (-5.6, -3.5) for the EQ-5D-5L index, and -7.9 (-9.6, -6.3) for EQ-VAS. CONCLUSIONS: Disease progression negatively impacted HRQoL in patients with OC. PFS is clinically relevant, and prolonging PFS may preserve HRQoL.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chase DM, Marín MR, Backes F, et al. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022. PMID: 35851489. doi:10.1016/j.ygyno.2022.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。